Johnson & Johnson has spent years defending itself against talc claims that its baby powder caused cancer and has sometimes suffered costly losses. But the company has had success in appeals, and that trend continued Tuesday with the reversal of a $110 million verdict.
Merck has not given up on antibiotics. This year, Zerbaxa, an antibacterial combination product has had a label expansion and its newly approved Recarbio has met its endpoints in a phase 3 test against hospital-acquired and ventilator-associated bacterial pneumonia in adult patients that could lead to a label expansion.
After finding trace amounts of an “unexpected impurity,” Torrent Pharmaceuticals Limited has expanded its voluntary recall of losartan potassium tablets. The impurity is N-Methylnitrosobutyric acid.
The expanded recall includes an additional three lots of losartan potassium tablets USP and two lots of losartan potassium/ydrochlorothiazide tablets. Only lots of losartan NMBA above the acceptable daily intake levels released by the FDA are being recalled.
According to a recent article by Fierce Pharma the top 10 best-paying place to work in biopharma are:
AstraZeneca’s Imfinzi, which enables the immune system to detect and attack certain cancer cells, when combined with chemotherapy has been shown to lengthen patient’s lives with an aggressive type of lung cancer by nearly to three months.
Pivotal phase 3 data for The Medicines Company’s longer-lasting PCSK9 cholesterol fighter shows the drug is at least as safe and effective as its two marketed rivals - Amgen's Repatha and Sanofi and Regeneron's Praluent.
After a six week trial a judge has ruled that Johnson & Johnson must pay $572 million as part of an opioid abatement plan. J&J fought hard against Oklahoma's claims the company played a "kingpin" role in the state’s opioid epidemic, but its lawyers fell short in those efforts.
Nabriva has received its first FDA approval for Xenleta, a drug used to treat community-acquired bacterial-pneumonia (CABP) in adults. CABP affects around 5 million Americans each year. The drug, which can be given orally or intravenously, is the first in a new class of antibiotics called pleuromutilins,
Last week Bayer discovered that vials of one of their top-selling hemophilia drugs had been filled with the wrong medicine. The vials are labeled as containing Kegenate FS but they actually are filled with VIII hemophilia A treatment Jivi. All but 990 vials were caught before they made it into the marketplace.
The FDA has accepted a Novartis’ biologics application for its sickle cell disease candidate crizanlizumab (SEG101). This puts the drug under priority review, which slashes four months off its evaluation time to just six months in total.
After its May 2019 FDA approval, Jazz Pharmaceuticals is hitting the ground running with its launch of Sunosi, used to treat narcolepsy, but also for patients with obstructive sleep apnea (OSA).
Researchers at the University of Pennsylvania have found a new method for attacking MYC, a cancer-causing gene that has proven difficult to target with drugs.
AbbVie, a biopharmaceutical company, said it plans to buy Botox maker Allergan for about $63 billion, to help reduce its reliance on blockbuster arthritis treatment Humira.
Humira, the world's best-selling drug, already has cheaper versions available in Europe and has its US patents expiring in 2023.
After the Drug Enforcement Agency marked Sunosi with a Schedule IV designation, Jazz Pharmaceuticals, a biopharmaceutical company, is now planning a July launch.
FiercePharma has calculated the top CEO pay packages in biopharma in 2018. The salaries range from nearly $60 million down to $16 million. Amongst the data are some notable trends. First, no women made the list. Emma Walmsley, Big Pharma’s only women CEO had a pay package of $7.75 million, which if doubled still would not make the top 20. Other Big Pharma CEOs not on the list are Novartis, Roche and Sanofi.
As ASCO 2019 comes to an end in Chicago, click here to learn about all the latest oncology news.
After Friday’s FDA approval of Novartis’ gene therapy drug, the company has set a $2.1 million price tag for the one-time treatment. Zogensma has been approved for treatment for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA). The price will make it the world’s most expensive drug.
Paul McKenzie, who joined Biogen in 2016 as executive vice president of pharmaceutical operations and technology, has been named Chief Operating Officer at CSL Behring in King of Prussia, PA. CSL Behring, a leading global biotech company, saw its share price rise 30% in 2018,
The FDA has moved back the PDUFA action date to August for Daiichi Sankyo’s quizartinib, used for the treatment of acute myeloid leukemia (AML). Current Phase 3 data, linked FLT3 inhibitor quizartinib to a 1.5 month improvement in overall survival (OS) over chemotherapy.
On Wednesday, the HHS announced a ruling that will require drugmakers to provide the price of their products to the public in TV commercials and they only have about two months to make the changes.